Lipocine Receives Complete Response Letter for TLANDO(TM) from U.S. FDA

SALT LAKE CITY, Nov. 11, 2019 -- (Healthcare Sales & Marketing Network)-- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the United States F...Biopharmaceuticals
Lipocine, TLANDO, testosterone replacement therapy